Source disclosure: February 20, 2026
MediciNova,Inc. [4875.T]
TOKYO, Feb 20 (Pulse News Wire) – Medicinova,inc. (4875.T) reported a lower net profit of $12 million for the fiscal year ended December 31, 2025, compared to a loss of $11 million in the previous year.
Revenue was $0.4 million, primarily due to a contract with Mayo Foundation concluded in December 2024. Research and development expenses remained stable at approximately $20.8 million for both years, but increased costs associated with ongoing clinical trials are expected in fiscal 2026. Due to potential impacts on strategic partnerships and licensing activities, the company did not disclose specific revenue or operating profit forecasts for the upcoming fiscal year ending December 31, 2026.
However, management expects higher research and development expenditures, estimating operational expenses of $16.2 million for the next fiscal year. As of December 31, 2025, the company's cash and cash equivalents stood at $30.8 million, with working capital estimated at $27.2 million. Management believes this level of expenditure is sufficient to fund ongoing product development efforts aimed at commercializing its pipeline products.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing